All In Biotech

Drug Trial Radar · NCT03269994

Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy?

A Phase III Multicenter, Open Label Randomized Controlled Trial of Cefoxitin Versus Piperacillin-Tazobactam as Surgical Antibiotic Prophylaxis in Patients Undergoing Pancreatoduodenectomy

Last checked: Nov 20, 2026Latest source record: Oct 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 967 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

967

Actual

Start

Nov 21, 2017

Primary completion

Jan 28, 2025

Study completion Jan 28, 2025

Sponsor

Lead sponsor
Memorial Sloan Kettering Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Indiana University; Massachusetts General Hospital; Thomas Jefferson University; Washington University School of Medicine; Advocate Illinois Masonic Medical Center; Baptist Memorial Health Care Corporation; Baylor Scott and White Health; The Cleveland Clinic; Emory University; Fox Chase Cancer Center; Gundersen Lutheran Medical Center; Hackensack Meridian Health; Hamilton Health Sciences Center; Intermountain Health Care, Inc.; Jersey Shore Medical Center (Hackensack Meridian); Johns Hopkins University; Montefiore Medical Center/Albert Einstein College of Medicine; North Shore University HealthSystem; Milton S. Hershey Medical Center; Rhode Island Hospital; Stony Brook Medicine; Sunnybrook Health Sciences Centre; Temple University; Ohio State University; The Ottowa Hospital/University of Ottowa; University of California, Davis; University of Chicago; University of Iowa; University of Texas Southwestern Medical Center; University of Utah; University of Wisconsin, Madison; Providence Health & Services; Albany Medical College; Northwestern University; Universtiy of Mississippi Medical Center; Mount Sinai Hospital, New York; Brody School of Medicine at East Carolina University
First posted
Sep 1, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to figure out which commonly used antibiotic, cefoxitin or piperacillin-tazobactam, is better at decreasing the rate of surgical site infections after pancreatoduodenectomy.

Conditions

  • Pancreatic Cancer
  • Pancreas Cancer
  • Pancreatic Diseases

Interventions

  • CefoxitinDrug

    Participants will receive one dose of cefoxitin within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.

  • Piperacillin-tazobactamDrug

    Participants will receive one dose of piperacillin-tazobactam within 1 hour of incision time, redosed every 2-4 hours in the operating room until closure of the incision, and discontinued within 24 hours after anesthesia end time.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Evaluated for the Effectiveness of Cefoxitin as a Surgical Antibiotic Prophylaxis.Time frame: 30 days

Locations

32 sites in 2 countries. Site status is shown where the registry gives one.

  • UC Davis Comprehensive Cancer Center

    Sacramento, California

  • Emory University School of Medicine

    Atlanta, Georgia

  • Northwestern Medicine (Data Collection)

    Chicago, Illinois

  • NorthShore University Health System

    Evanston, Illinois

  • Indiana University

    Indianapolis, Indiana

  • University of Iowa

    Iowa City, Iowa

  • Massachusetts General Hospital

    Boston, Massachusetts

  • University of Washington School of Medicine

    St Louis, Missouri

  • University of Nebraska Medical Center

    Omaha, Nebraska

  • Memorial Sloan Kettering Basking Ridge (Consent only)

    Basking Ridge, New Jersey

  • Hackensack Meridian Health / Hackensack University Medical Center Cancer Center

    Hackensack, New Jersey

  • Memorial Sloan Kettering Commack (Consent only)

    Commack, New York

  • Memoral Sloan Kettering Westchester (Consent only)

    Harrison, New York

  • Mount Sinai Hospital

    New York, New York

  • Mount Sinai West

    New York, New York

  • Memorial Sloan Kettering Cancer Center

    New York, New York

  • Montefiore Health Systems (Montefiore Medical Center)

    The Bronx, New York

  • Duke University

    Durham, North Carolina

  • Brody School of Medicine at East Carolina University

    Greenville, North Carolina

  • Ohio State University

    Columbus, Ohio

  • Providence Health & Services (Portland Med Ctr)

    Portland, Oregon

  • Pennsylvania State Hershey

    Hershey, Pennsylvania

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania

  • Baptist Memorial Healthcare

    Memphis, Tennessee

  • Baylor Scott & White Health

    Dallas, Texas

  • Intermountain Healthcare

    Murray, Utah

  • University of Utah

    Salt Lake City, Utah

  • Gundersen Lutheran Medical Foundation

    La Crosse, Wisconsin

  • University of Wisconsin

    Madison, Wisconsin

  • Hamilton Health Sciences Center (Juravinski Hospital)

    Hamilton, Ontario, Canada

  • Ottawa Hospital

    Ottawa, Ontario, Canada

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.